Jia Congli, Li Zhengquan, Guo Dong, Zhang Zhen, Yu Jingming, Jiang Guangdong, Xing Xiaobo, Ji Shengjun, Jin Feng
Weifang Medical University, Weifang, People's Republic of China.
Department of Laboratory Pathology, People's Liberation Army 80th Group Military Hospital, Weifang, People's Republic of China.
Onco Targets Ther. 2020 Dec 22;13:13087-13096. doi: 10.2147/OTT.S286893. eCollection 2020.
Brain metastases (BM) are severe incidents among patients with non-small cell lung cancer (NSCLC) and have been associated with significant morbidity and decreased survival; thus, new methods are required to improve clinical management. Magnetic resonance spectroscopy (MRS) allows noninvasive measurements of biochemical information from tumor tissue, providing clinically useful imaging biomarkers. The primary aim of this study was to explore the application of MRS in the assessment of tumor prognosis after stereotactic radiotherapy in NSCLC patients with BM.
MRS was performed on NSCLC patients attending Qingdao Center Hospital with suspected BM, and 68 patients were included in the survival analysis. The qualitative and quantitative parameters of MRS metabolites, such as choline (Cho), creatine (Cr), and N-acetyl-aspartate (NAA), were recorded. To select a cutoff for MRS metabolite parameters in the tumor and to distinguish patients who had recurrence, we performed an ROC curve analysis. Univariate and multivariate Cox regression analyses were used to assess the association between MRS metabolite parameters and clinical cancer prognosis.
The average age was 56 years. A total of 68 NSCLC patients underwent metabolic evaluation with single voxel proton MRS and were selected for retrospective analysis. According to the area under the curve (AUC) to predict recurrence, the MRS metabolite parameters were determined as Cho (AUC=0.550), Cr (AUC=0.415), NAA (AUC=0.524), NAA/Cr (AUC=0.600), Cho/Cr (AUC=0.723), and Cho/NAA (AUC=0.543). Cho and Cr predicted poor survival while Cho/Cr and NAA/Cr predicted improved survival (<0.05). In the multivariate model with adjustment to establish the potential role of MRS metabolite parameters, Cho/Cr showed a significant association with OS (=0.009) and PFS (=0.006) after stereotactic radiotherapy.
The positive results of this study indicate the predictive value of metabolic characteristics of BM detected with MRS for the outcome after stereotactic radiotherapy.
脑转移(BM)是非小细胞肺癌(NSCLC)患者中的严重事件,与显著的发病率和生存率降低相关;因此,需要新的方法来改善临床管理。磁共振波谱(MRS)能够对肿瘤组织的生化信息进行无创测量,提供具有临床应用价值的影像生物标志物。本研究的主要目的是探讨MRS在评估NSCLC脑转移患者立体定向放射治疗后肿瘤预后中的应用。
对青岛中心医院疑似脑转移的NSCLC患者进行MRS检查,68例患者纳入生存分析。记录MRS代谢物的定性和定量参数,如胆碱(Cho)、肌酸(Cr)和N-乙酰天门冬氨酸(NAA)。为选择肿瘤中MRS代谢物参数的临界值并区分复发患者,我们进行了ROC曲线分析。采用单因素和多因素Cox回归分析评估MRS代谢物参数与临床癌症预后之间的关联。
平均年龄为56岁。共有68例NSCLC患者接受了单体素质子MRS代谢评估,并被选入回顾性分析。根据预测复发的曲线下面积(AUC),确定MRS代谢物参数为Cho(AUC = 0.550)、Cr(AUC = 0.415)、NAA(AUC = 0.524)、NAA/Cr(AUC = 0.600)、Cho/Cr(AUC = 0.723)和Cho/NAA(AUC = 0.543)。Cho和Cr提示生存预后差,而Cho/Cr和NAA/Cr提示生存预后改善(<0.05)。在调整后的多因素模型中以确定MRS代谢物参数的潜在作用,Cho/Cr与立体定向放射治疗后的总生存期(OS,= 0.009)和无进展生存期(PFS,= 0.双因素方差分析)显著相关。
本研究的阳性结果表明,MRS检测到的脑转移代谢特征对立体定向放射治疗后的预后具有预测价值。